{"title":"Effectiveness of palliative care in the management of end-stage liver disease: a systematic review protocol.","authors":"Harshitha Manjunath, Aditi Manoj, Bhagya S, Sahana Rani S, Chithra Venkateswaran, Denny John","doi":"10.11124/JBIES-24-00454","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this systematic review is to evaluate the effectiveness of palliative care in treating adults with end-stage liver disease (ESLD), focusing on outcomes such as quality of life, quality of care, symptom burden, and patient satisfaction.</p><p><strong>Introduction: </strong>ESLD is a critical health issue, characterized by various devitalizing symptoms that negatively impact quality of life for patients. Palliative care, which is a specialty used to alleviate pain and control other manifestations of the disease, has been suggested across various studies for the management of quality of life and symptom burden in ESLD patients.</p><p><strong>Inclusion criteria: </strong>This review will include studies focusing on the use of palliative care for adults (≥18 years) with ESLD. Papers that focus on the comparison between palliative care and usual care or placebo will be included.</p><p><strong>Methods: </strong>MEDLINE (PubMed), Embase (Ovid), Cochrane (CENTRAL), CINAHL (EBSCOhost), Scopus, and Web of Science will be searched for published studies. Sources to be searched for unpublished literature will include Google Scholar, ProQuest Dissertations and Theses, Shodhganga, MedNar, OpenGrey, and the World Health Organization. Two independent reviewers will assess titles, abstracts, and full-text papers against the inclusion criteria. A third reviewer will resolve any discrepancies. Standardized JBI appraisal tools will be used to critically appraise eligible studies. Two independent reviewers will extract data. Meta-analysis will be conducted for outcomes, where feasible. If a meta-analysis cannot be conducted, the findings will be reported in a narrative format. Certainty of evidence will be reported using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.</p><p><strong>Review registration: </strong>PROSPERO CRD42024586855.</p>","PeriodicalId":36399,"journal":{"name":"JBI evidence synthesis","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JBI evidence synthesis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11124/JBIES-24-00454","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The aim of this systematic review is to evaluate the effectiveness of palliative care in treating adults with end-stage liver disease (ESLD), focusing on outcomes such as quality of life, quality of care, symptom burden, and patient satisfaction.
Introduction: ESLD is a critical health issue, characterized by various devitalizing symptoms that negatively impact quality of life for patients. Palliative care, which is a specialty used to alleviate pain and control other manifestations of the disease, has been suggested across various studies for the management of quality of life and symptom burden in ESLD patients.
Inclusion criteria: This review will include studies focusing on the use of palliative care for adults (≥18 years) with ESLD. Papers that focus on the comparison between palliative care and usual care or placebo will be included.
Methods: MEDLINE (PubMed), Embase (Ovid), Cochrane (CENTRAL), CINAHL (EBSCOhost), Scopus, and Web of Science will be searched for published studies. Sources to be searched for unpublished literature will include Google Scholar, ProQuest Dissertations and Theses, Shodhganga, MedNar, OpenGrey, and the World Health Organization. Two independent reviewers will assess titles, abstracts, and full-text papers against the inclusion criteria. A third reviewer will resolve any discrepancies. Standardized JBI appraisal tools will be used to critically appraise eligible studies. Two independent reviewers will extract data. Meta-analysis will be conducted for outcomes, where feasible. If a meta-analysis cannot be conducted, the findings will be reported in a narrative format. Certainty of evidence will be reported using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.
目的：本系统综述的目的是评估姑息治疗治疗终末期肝病（ESLD）的有效性，重点关注生活质量、护理质量、症状负担和患者满意度等结果。ESLD是一种严重的健康问题，其特点是各种失活症状对患者的生活质量产生负面影响。姑息治疗是一种用于减轻疼痛和控制疾病其他表现的专科，已在各种研究中被建议用于管理ESLD患者的生活质量和症状负担。纳入标准：本综述将纳入关注ESLD成人（≥18岁）姑息治疗使用的研究。将包括关注缓和治疗与常规治疗或安慰剂比较的论文。方法：检索MEDLINE （PubMed）、Embase （Ovid）、Cochrane （CENTRAL）、CINAHL （EBSCOhost）、Scopus和Web of Science等已发表的研究。搜索未发表文献的来源包括谷歌Scholar、ProQuest dissertation and Theses、Shodhganga、MedNar、OpenGrey和World Health Organization。两名独立审稿人将根据纳入标准评估标题、摘要和全文论文。第三位审稿人将解决任何差异。标准化的JBI评估工具将用于严格评估合格的研究。两名独立审稿人将提取数据。如果可行，将对结果进行荟萃分析。如果不能进行荟萃分析，研究结果将以叙述形式报告。证据的确定性将使用建议、评估、发展和评价分级（GRADE）方法进行报告。审核注册：PROSPERO CRD42024586855。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
